# Aramis Biosciences

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/aramis-biosciences

- Industry: Biotechnology
- Headquarters: Boston, US
- Website: www.aramisbio.com
- Total disclosed funding: $11M
- Latest round: Series A (Dec 15, 2021)
- Investors on record: 1

## About

Aramis Biosciences, Inc. is focused on developing innovative therapies for ocular surface diseases, particularly targeting Dry Eye Disease through its clinical pipeline, including its lead candidate A197.Aramis Biosciences, Inc. is a clinical-stage company founded in 2018, headquartered in Boston, US. The company specializes in developing therapies for ocular surface diseases. Led by CEO David Tierney, the firm was founded by Reza Dana and Sunil Chauhan. The company has successfully raised USD 10.5 mn in Series A funding led by Safar Partners in December 2021, bringing the total amount raised to USD 10.5 mn through two deals.Aramis Biosciences specializes in the development of disease-modifying therapies for ocular surface diseases, focusing primarily on Dry Eye Disease (DED). They are advancing A197, a lead product candidate in clinical trials aimed at addressing unmet medical needs in DED. The U.S. has approximately 17.8 million diagnosed DED patients, with fewer than 1 million receiving FDA-approved therapies. The company targets healthcare providers and specialists in ophthalmology, planning to serve DED patients globally, starting from the U.S.Aramis Biosciences operates as a clinical-stage company, emphasizing the development and potential commercialization of its therapies. Revenue strategies may include partnerships with pharmaceutical firms and healthcare institutions to advance A197 and other candidates. Revenue could also be generated from direct sales to providers administering DED treatments, following FDA approval of A197 and future products.In December 2021, Aramis Biosciences, Inc. raised USD 10.5 mn in Series A funding led by returning investor Safar Partners. The company intends to leverage this funding to advance its pipeline, particularly focusing on A197, a first-in-class topical immunomodulatory agent, through Phase II clinical proof of concept for Dry Eye Disease treatment. Future plans may also involve expanding into international markets as development progresses, enhancing their presence in ophthalmology and related sectors.

## Funding rounds

- Series A, Dec 15, 2021, $11M — Safar Partners
- Seed, Jan 1, 2020 — Safar Partners

## Investors

- Safar Partners (https://capitalatlas.ai/funds/safar-partners) — Seed, Series A